INHIBIKASE THERAPEUTICS ($IKT) is expected to release its quarterly earnings data on Tuesday, March 25th after market close, per Finnhub. Analysts are expecting ...

A downtrend has been apparent in Inhibikase Therapeutics, Inc. (IKT) lately. While the stock has lost 15.4% over the past two weeks, it could witness a trend reversal as a hammer chart pattern was ...

BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), today announced the appointment of two ...

Reveal insider sentiment with alternative data that tracks buy and sell trades made by top managers and company directors.

Chris Cabell, MD MHS FACC Appointed President and Head of Research & Development --- --- John Adams, PhD Appointed Chief Scientific Officer --- --- Vince Aurentz to join Inhibikase Board of ...